A Phase II Study of Checkpoint Blockage Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

February 23, 2021

Clinical Trial Information

Protocol – Alliance A071702

SCHEMA A071702

Please Note – Below is a brief description of eligibility, please contact GHCI Research Department to discuss full eligibility.


  1. Histologically confirmed glioblastoma (WHO grade IV) presenting at first or second recurrence including secondary glioblastoma.
  2. Presence of measurable disease, as defined by a bidimensionally measurable lesion on MRI with a minimum diameter of 10 mm in both dimensions, prior to resection or biopsy of recurrent tumor.
  3. Tissue available from surgical resection or biopsy of recurrent tumor ≤14 days prior to pre-registration, or planned surgery or biopsy of recurrent tumor ≤14 days after pre-registration.
  4. Does not require > 4 mg dexamethasone beyond the perioperative period defined as the time ≤ 2 weeks after surgical procedure.
  5. No active autoimmune disease or history of autoimmune disease.
  6. No prior treatment with checkpoint blockade therapies (anti-CTLA4, anti-PD1/PD-L1) or bevacizumab.
  7. Age ≥ 18 years.
  8. ECOG Performance Status ≤ 2.

Genesys Hurley Cancer Institute

302 Kensington Avenue
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium


Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.